Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Raw Materials (2018 - 2025)

Neurocrine Biosciences filings provide 8 years of Raw Materials readings, the most recent being $31.9 million for Q1 2025.

  • On a quarterly basis, Raw Materials rose 76.24% to $31.9 million in Q1 2025 year-over-year; TTM through Mar 2025 was $31.9 million, a 76.24% increase, with the full-year FY2024 number at $33.7 million, up 56.74% from a year prior.
  • Raw Materials hit $31.9 million in Q1 2025 for Neurocrine Biosciences, down from $33.7 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $33.7 million in Q4 2024 to a low of $11.2 million in Q4 2021.
  • Median Raw Materials over the past 5 years was $21.4 million (2023), compared with a mean of $21.7 million.
  • Biggest five-year swings in Raw Materials: tumbled 32.53% in 2021 and later surged 79.17% in 2023.
  • Neurocrine Biosciences' Raw Materials stood at $11.2 million in 2021, then grew by 7.14% to $12.0 million in 2022, then surged by 79.17% to $21.5 million in 2023, then skyrocketed by 56.74% to $33.7 million in 2024, then decreased by 5.34% to $31.9 million in 2025.
  • The last three reported values for Raw Materials were $31.9 million (Q1 2025), $33.7 million (Q4 2024), and $23.7 million (Q3 2024) per Business Quant data.